01-03-2017
Photo: Courtesy of Teva
Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone (buprenorphine and naloxone) and Subutex (buprenorphine).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Actavis, Teva, Zubsolv, Orexo, Suboxone, Subutex, US District Court for the District of Delaware, patent, patent infringement
Teva drops lawsuit with Amicus over Creates Act dispute
07-09-2021
Fed Circ upholds three Teva patents, axes others
19-08-2021
Teva sues two Indian generics over Huntington’s treatment
06-07-2021
Fed Circ to rehear $235m ‘skinny label’ case
10-02-2021
Teva fails to reclassify MS drug to thwart generics
05-01-2021
Bausch Health settles generic dispute with Actavis
13-09-2018
